Coloplast (BMV:0QBO N) - Cours de l'action, nouvelles et analyse

0QBO N Aperçu des actions

Engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. Plus de détails

0QBO N analyse fondamentale
Score flocon de neige
Évaluation	1/6
Croissance future	3/6
Performances passées	3/6
Santé financière	2/6
Dividendes	3/6

Récompenses

Les bénéfices devraient augmenter 10.99% par an

Les bénéfices ont augmenté de 1.2% au cours de l'année écoulée

Analyse des risques

Les actions sont très illiquides

A un niveau d'endettement élevé

Coloplast A/S Concurrents

Cooper Companies

NasdaqGS:COO

US$19.8b

Alcon

SWX:ALC

CHF 37.8b

HOYA

TSE:7741

JP¥7.0t

Align Technology

NasdaqGS:ALGN

US$16.7b

Historique des prix et performances

Résumé des plus hauts, des changements et des baisses de prix pour Coloplast
Historique des cours de bourse
Prix actuel de l'action	DKK 2,082.59
Plus haut sur 52 semaines	DKK 2,427.29
Plus bas sur 52 semaines	DKK 2,082.59
Bêta	0.22
1Variation sur 1 mois	0%
Variation sur 3 mois	n/a
Variation sur 1 an	n/a
3Variation sur 3 ans	n/a
Variation sur 5 ans	26.87%
Évolution depuis l'introduction en bourse	65.47%

Nouvelles et mises à jour récentes

Recent updates

Rendement pour les actionnaires

	0QBO N	MX Medical Equipment	MX Marché
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendement vs Industrie: Données insuffisantes pour déterminer la performance de 0QBO N par rapport au secteur MX Medical Equipment.

Rendement vs marché: Données insuffisantes pour déterminer la performance de 0QBO N par rapport au marché MX.

Volatilité des prix

Is 0QBO N's price volatile compared to industry and market?
0QBO N volatility
0QBO N Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Cours de l'action stable: 0QBO N n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.

Volatilité au fil du temps: Données insuffisantes pour déterminer l'évolution de la volatilité de 0QBO N au cours de l'année écoulée.

À propos de l'entreprise

Fondée	Salariés	PDG	Site web
1954	14,973	Kristian Villumsen	www.coloplast.com

Coloplast A/S Résumé des fondamentaux

Comment les bénéfices et les revenus de Coloplast se comparent-ils à sa capitalisation boursière ?
0QBO N statistiques fondamentales
Capitalisation boursière	Mex$499.55b
Bénéfices(TTM)	Mex$12.47b
Recettes(TTM)	Mex$62.55b

40.0x

Ratio P/E

8.0x

Ratio P/S

Le site 0QBO N est-il surévalué ?

Voir Juste valeur et analyse de l'évaluation

Bénéfices et recettes

Principales statistiques de rentabilité tirées du dernier rapport sur les bénéfices (TTM)
0QBO N compte de résultat (TTM)
Recettes	DKK 24.07b
Coût des recettes	DKK 7.68b
Marge brute	DKK 16.39b
Autres dépenses	DKK 11.59b
Les revenus	DKK 4.80b

Derniers bénéfices déclarés

Mar 31, 2023

Prochaine date de publication des résultats

Aug 17, 2023

Résultat par action (EPS)	22.60
Marge brute	68.09%
Marge bénéficiaire nette	19.94%
Ratio dettes/capitaux propres	295.4%

Quelles ont été les performances à long terme de 0QBO N?

Voir les performances historiques et les comparaisons

Dividendes

2.2%

Rendement actuel des dividendes

88%

Ratio de distribution

0QBO N Aperçu des actions

Récompenses

Analyse des risques

Coloplast A/S Concurrents

NasdaqGS:COO

US$19.8b

SWX:ALC

CHF 37.8b

TSE:7741

JP¥7.0t

NasdaqGS:ALGN

US$16.7b

Historique des prix et performances

Nouvelles et mises à jour récentes

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Recent updates

Coloplast A/S Announces Kerecis Includes on List of Covered Products for Diabetic Foot Ulcers in Final LCD Policy

Coloplast A/S to Report Nine Months, 2025 Results on Aug 19, 2025

Coloplast A/S Recommends the Distribution of Year-End Dividend

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Less than half of directors are independent

First quarter 2023 earnings released: EPS: kr.5.31 (vs kr.5.67 in 1Q 2022)

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Less than half of directors are independent

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Less than half of directors are independent

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Upcoming dividend of kr.14.00 per share

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Coloplast A/S Provides Earnings for the Year 2021

Investor sentiment improved over the past week

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Rendement pour les actionnaires

Volatilité des prix

À propos de l'entreprise

Coloplast A/S Résumé des fondamentaux

40.0x

8.0x

Bénéfices et recettes

Dividendes

2.2%

88%